731 844
Table 1 – Patient characteristics
Variable
Total
Low risk
Int risk
High risk
N
= 598 640
N
= 217 047 (36.3%)
N
= 261 997 (43.8%)
N
= 119 596 (20.0%)
Age, mean (STE)
64.7 (0.011)
63.3 (0.018)
64.7 (0.017)
67.3 (0.025)
N
(%)
N
(%)
N
(%)
N
(%)
Race
Non-Hispanic White
470 557 (78.6)
175 673 (80.9)
[3_TD$DIFF]
205
[4_TD$DIFF]
461 (78.4)
89 423 (74.8)
Hispanic
21 872 (3.7)
7463 (3.4)
9406 (3.6)
5003 (4.2)
Black
894 85 (14.9)
28 397 (13.1)
39 813 (15.2)
21 275 (17.8)
Other
16 726 (2.8)
5514 (2.5)
7317 (2.8)
3895 (3.3)
Insurance typ
e aUninsured
9843 (1.6)
2872 (1.3)
4185 (1.6)
2786 (2.3)
Medicaid
12 835 (2.1)
3683 (1.7)
5517 (2.1)
3635 (3.0)
Younger Medicare
24 032 (4.0)
8846 (4.1)
10 491 (4.0)
4695 (3.9)
Older Medicare
244 712 (40.9)
77 327 (35.6)
107 371 (41.0)
60 014 (50.2)
Government
5054 (0.8)
1443 (0.7)
2172 (0.8)
1439 (1.2)
Private
302 164 (50.5)
122 876 (56.6)
132 261 (50.5)
47 027 (39.3)
Diagnosis year
2004
55 104 (9.2)
21 681 (10.0)
22 138 (8.4)
11 285 (9.4)
2005
55 252 (9.2)
21 221 (9.8)
22 914 (8.7)
11 117 (9.3)
2006
62 673 (10.5)
23 741 (10.9)
26 683 (10.2)
12 249 (10.2)
2007
68 593 (11.5)
25 239 (11.6)
30 313 (11.6)
13 041 (10.9)
2008
73 394 (12.3)
25 230 (11.6)
34 068 (13.0)
14 096 (11.8)
2009
72 967 (12.2)
24 615 (11.3)
34 161 (13.0)
14 191 (11.9)
2010
72 805 (12.2)
27 358 (12.6)
30 829 (11.8)
14 618 (12.2)
2011
76 145 (12.7)
27 766 (12.8)
32 966 (12.6)
15 413 (12.9)
2012
61 707 (10.3)
20 196 (9.3)
27 925 (10.7)
13 586 (11.4)
Modified Charlson comorbidity score
0
500 002 (83.5)
184 964 (85.2)
217 094 (82.9)
97 944 (81.9)
1
79 368 (13.3)
26 335 (12.1)
36 287 (13.9)
16 746 (14.0)
2
19 270 (3.2)
5748 (2.6)
8616 (3.3)
4906 (4.1)
Clinical T stage
T1
414 770 (69.3)
184 132 (84.8)
168 876 (64.5)
61 762 (51.6)
T2
166 795 (27.9)
32 915 (15.2)
93 121 (35.5)
40 759 (34.1)
T3/T4
17 075 (2.9)
0 (0.0)
0 (0.0)
17 075 (14.3)
Combined Gleason score
2-6
279 144 (46.6)
217 047 (100)
448 96 (17.1)
17 201 (14.4)
7
243 656 (40.7)
0 (0.0)
217 101 (82.9)
26 555 (22.2)
8-10
75 840 (12.7)
0 (0.0)
0 (0.0)
75 840 (63.4)
Prostate specific antigen level
<
10 ng/ml
471 929 (78.8)
217 047 (100)
204 247 (78.0)
50 635 (42.3)
10–20 ng/ml
75 445 (12.6)
0 (0.0)
57 750 (22.0)
17 695 (14.8)
>
20 ng/ml
51 266 (8.6)
0 (0.0)
0 (0.0)
51 266 (42.9)
Primary treatment
Prostatectomy
269 491 (45.0)
91 684 (42.2)
135 847 (51.9)
41 960 (35.1)
Brachytherapy
9640 (1.6)
3037 (1.4)
4594 (1.8)
2009 (1.7)
External beam radiotherapy
168 397 (28.1)
43 146 (19.9)
74 916 (28.6)
50 335 (42.1)
Cryotherapy
78 709 (13.1)
46 194 (21.3)
25 040 (9.6)
7475 (6.3)
Primary androgen deprivation therapy
22 351 (3.7)
5266 (2.4)
7467 (2.9)
9618 (8.0)
Observation
50 052 (8.4)
27 720 (12.8)
14 133 (5.4)
8199 (6.9)
Income level
<
$30 000
74 049 (12.4)
24 397 (11.2)
32 009 (12.2)
17 643 (14.8)
$30 000–34 999
100 659 (16.8)
34 986 (16.1)
43 996 (16.8)
21 677 (18.1)
$35 000–45 999
162 760 (27.2)
58 232 (26.8)
71 466 (27.3)
33 062 (27.6)
$46 000
261 172 (43.6)
99 432 (45.8)
114 526 (43.7)
47 214 (39.5)
Treatment facility type
Community cancer program
51 681 (8.6)
17 903 (8.2)
21 422 (8.2)
12 356 (10.3)
Comprehensive community cancer program 277 608 (46.4)
100 032 (46.1)
120 279 (45.9)
57 297 (47.9)
Teaching/research hospital
143 446 (24.0)
52 186 (24.0)
63 298 (24.2)
27 962 (23.4)
NCI network cancer center
83 495 (13.9)
31 564 (14.5)
38 201 (14.6)
13 730 (11.5)
Other
42 410 (7.1)
15 362 (7.1)
[6_TD$DIFF]
18 797 (7.2)
8251 (6.9)
US census region
Northeast
127 019 (21.2)
48 288 (22.2)
54 825 (20.9)
23 906 (20.0)
Midwest
222 881 (37.2)
81 801 (37.7)
95 019 (36.3)
46 061 (38.5)
South
148 228 (24.8)
51 880 (23.9)
65 862 (25.1)
30 486 (25.5)
West
100 512 (16.8)
35 078 (16.2)
46 291 (17.7)
[7_TD$DIFF]
19 143 (16)
Int = intermediate; NCI = National Cancer Institute; STE = standard error.
a
Younger Medicare refers to patients aged 18–64 yr receiving Medicare coverage while Older Medicare refers to those aged 65 yr or older.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 2 9 – 7 3 7
731